Market Newsdesk

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to the company. Dr. Varner currently serves as Professor in the Departments of Pathology and Medicine at the Moores Cancer Center at the University of California, San Diego (UCSD).

“We are pleased to announce Dr. Varner as a scientific advisor to our company and welcome the opportunity to work with an expert that is local to San Diego and has a world-renowned reputation in the area of cancer biology,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We look forward to Dr. Varner’s contributions as we continue to advance our mechanistic understanding of Neuropilin-2 (NRP2) as a potential target in solid tumors, including its associated signaling pathways and interaction with VEGF, one of its primary ligands. Her expertise in the areas of myeloid cell biology and tumor macrophage signal transduction lends well to our emerging NRP2 antibody program, which includes ATYR2810 and additional discovery stage candidates.”

“Our recent poster presented at the 2021 Virtual Keystone Symposia: Tumor Metabolism and the Microenvironment demonstrates that NRP2 is highly expressed on key immune cells in the tumor microenvironment, providing further validation of NRP2 as a regulator of solid tumor progression. Research continues to support NPR2 as a compelling target for potential therapeutic approaches to treat certain aggressive cancers where high expression of NRP2 is implicated, and aTyr is at the forefront of the effort to better understand NRP2 and its signaling pathways,” said Dr. Shukla.

Dr. Varner noted, “I look forward to serving on the scientific advisory board of aTyr, a clear leader in the development of anti-cancer therapeutics with their NRP2-based antibody therapeutics program.”

Dr. Varner joined UCSD in the Department of Medicine in 1997 and the Department of Pathology in 2012. As a member of the Moores Cancer Center, her research is focused on the role of inflammation in cancer. Her work, which recently appeared in Cancer Cell, Nature and Cancer Discovery, has identified novel mechanisms by which macrophages promote tumor growth and has developed new approaches to treat cancer patients by targeting tumor macrophage signal transduction. Dr. Varner has a particular interest in mentoring and promoting equity and diversity; she has served as the Chair of the Academic Senate Committee of Diversity and Equity, as UC San Diego representative to the Universities of California Academic Senate Committee on Diversity (UCAAD), and as a member of the Academic Senate/Health Sciences Research Grant Committee, the Senate-Administration Faculty Salary Equity Review Committee and the Chancellor’s Advisory Committee on the Status of Women. She has also served as the Chair of the Moores Cancer Center Space Advisory Committee, and as a member of the Medical Scientist Training Program Recruitment and Admissions Committee, the Department of Medicine Appointments and Promotions Committee, the Biomedical Sciences Graduate Admission Committee and the School of Medicine Recruitment and Admission Committee. She has served as Chair of the NIH Tumor Microenvironment review panel and of several NIH Special Emphasis reviews panel. Dr. Varner is a Fulbright fellow and recipient of the AACR- Landon Foundation Innovator Award for International Collaboration and the Lustgarten Foundation Innovator Award for Pancreatic Cancer Research.

Abo
ut NRP2

Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses. In many forms of cancer, high NRP2 expression is associated with worse outcomes. NRP2 can interact with multiple ligands and co-receptors through distinct domains to influence their functional roles, making it a potential drug target with multiple distinct therapeutic applications. NRP2 interacts with type 3 semaphorins and plexins to impact inflammation and with forms of vascular endothelial growth factor (VEGF) and their receptors, to impact lymphangiogenesis. In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs. aTyr is currently investigating NRP2 receptor biology, both internally and in collaboration with key academic thought leaders, as a novel target for new product candidates for a variety of diseases, including cancer and inflammation.

Abo
ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of NRP2 antibodies, including ATYR2810; timelines and plans with respect to certain development activities; and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
[email protected]

FOLSOM, NJ, March 10, 2021 (GLOBE NEWSWIRE) —                                                                                                 Media Contact: Dominick DiRocco
(609) 561-9000 ext. 4262

[email protected]

                                                                                                          Investor Contact: Dan Fidell
(609) 561-9000 ext. 7027
[email protected]

FOR IMMEDIATE RELEASE

SJI CEO Mike Renna Honored on NJ Influencers “Power List” along with Board Members

FOLSOM, NJ, March 10, 2021 – SJI’s (NYSE: SJI) President and CEO, Mike Renna, and three fellow members of SJI’s Board of Directors, Keith Campbell, Kevin O’Dowd and Chris Paladino, were recognized for their vision and leadership in New Jersey by being named to the ROI Influencers: Power List 2021.

Renna was included in the “Executives” section of ROI-NJ’s “Power List 2021,” where he was recognized for “making a push to make the company more relevant in more parts of the state, while doing his part to help revitalize Atlantic City.”

Under Renna’s leadership, SJI (a 100+ year-old company) now operates one of the most modern, reliable, and resilient energy delivery systems in the country. With the integration of Elizabethtown Gas now complete, SJI has grown to over 1,100 employees and 700,000 customers with a new vision—to build a clean future and advance critical decarbonization efforts by 2050.

In addition to Renna’s recognition, several of the members of SJI’s Board of Directors were also honored. SJI Director Keith Campbell, who has served on the board for more than 20 years, also made the ROI-NJ Top Executives for 2021 list. Board member Kevin O’Dowd ranked number 14 on the Top 30 List of Influencers for his role as co-president and CEO of Cooper University Health Care, which took the lead providing critical services to the southern region of New Jersey early in the COVID-19 pandemic. Additionally, Director Chris Paladino, president of DEVCO, ranked number 19 on the Top 30 List of Influencers for his “transformative projects up and down the state.” ROI staff noted that Paladino is a person who “all leaders seek out for insights.”

“With recognition on the Power List 2021, ROI-NJ confirms that SJI’s Board of Directors is composed of some of the most talented, dedicated and respected leaders who put SJI at the forefront of utility innovation, helping us deliver safe, reliable, affordable clean energy for a better today and tomorrow,” said Joseph M. Rigby, Chairman, SJI Board of Directors.

The annual ROI Influencers Power List is composed by staff who follow newsmakers and consider recommendations from people in dozens of industries. For more information about SJI and its subsidiaries, please visit sjindustries.com.

About SJI

SJI (NYSE: SJI), an energy services holding company based in Folsom, NJ, delivers energy services to its customers through three primary subsidiaries. SJI Utilities, SJI’s regulated natural gas utility business, delivers safe, reliable, affordable natural gas to approximately 700,000 South Jersey Gas and Elizabethtown Gas customers in New Jersey. SJI’s non-utility businesses within South Jersey Energy Solutions promote efficiency, clean technology and renewable energy by providing customized wholesale commodity marketing and fuel management services; and developing, owning and operating on-site energy production facilities. SJI Midstream houses the company’s interest in the PennEast Pipeline Project. For more information about SJI and its subsidiaries, please visit sjindustries.com.

###

Ottawa, March 10, 2021 (GLOBE NEWSWIRE) — Ottawa, March 10, 2021 – The Conference Board of Canada has released its latest forecast of provincial economic activity and finds a broad-based recovery taking place aided by the rollout of COVID-19 vaccines and a rebound in energy, tourism, and exports.

 

The Conference Board expects every province to record a sharp rebound in real gross domestic product (GDP) growth this year as the rollout of vaccines leads to the removal of provincial restrictions on economic activity and travel. The recovery will receive a boost from pent-up demand and the fact that millions of Canadians who managed to keep their jobs have accumulated a sizable amount of savings.

 

“The news of successful vaccines against COVID-19 has provided optimism about ending the health crisis and lifting battered economies all around the world out of the deepest recession in modern times,” says Pedro Antunes, Chief Economist at The Conference Board of Canada. “Our view is that consumers will lead the recovery over the second half of 2021 as COVID-19 cases dissipate and economic prospects and consumer confidence improves.”

 

Unable to travel, Canadian households have saved up or redirected the roughly $50 billion in spending that occurs abroad each year. Aggregate household savings swelled from $18 billion in 2019, to our estimate of over $200 billion in 2020. Even with a rebound in spending, household balance sheets will remain in great shape in 2021, averaging $113 billion, roughly five times what households held in savings in the four years prior to the pandemic.

 

Additionally, The Conference Board of Canada expects world oil prices and other commodity prices to continue to recover over the near term, providing a much-needed boost to resource sector investment.  

 

Federal stimulus measures are estimated to have been more than $280 billion in 2020, or the equivalent of 12 per cent of GDP. Once the crisis is past, the government will likely rein in spending to keep the deficit under control. As a result, growth in federal government consumption is expected to slow to two per cent growth in 2021 and then average annual growth of essentially zero between 2022 and 2025.  

 

While Canada’s economy has recovered from the shutdowns imposed in March and April of last year, it remains a long way from normal. Employment remains 4.4 per cent below pre-COVID levels, still reflective of a very deep recession. Many industries will not be able to fully recover until well into 2021, notably retail, culture and recreation, food and beverage services and anything tourism related. And the impact of COVID-19 on the global economy has decimated Canadian exports, especially for oil and natural gas.

 

The outlook for provinces across Canada this year is as follows:

 

Newfoundland: After falling by an estimated 3.5 per cent in 2020, Newfoundland and Labrador’s real GDP is forecast to grow by 2.8 per cent in 2021 and 4.7 per cent in 2022, as the province continues to recover from the impacts of Covid-19.

 

P.E.I: Prince Edward Island’s economy is currently undergoing one of the largest negative shocks in its history. The worst should be behind the Island province, however. After falling 4.3 per cent in 2020, P.E.I.’s economy should make a full recovery, growing 4.9 per cent in 2021 and 5.0 per cent in 2022.

 

Nova Scotia: Nova Scotia’s economic recovery will pick up its pace this year on the back of looser restrictions and a fast rebound in the labour market. We expect that the economic reopening early in the year will support a fast rebound of in Nova Scotia’s economic activity, especially on the services-producing side. Nova Scotia’s real GDP is expected to rebound by 4.1 per cent in 2021, after shrinking by 4.0 per cent in 2020.

 

New Brunswick: New Brunswick has been relatively successful at controlling the spread of COVID-19 and the avoidance of some of the shutdown measures implemented in central Canada enabled a shallower recession last year compared with most other provinces. Real GDP dropped by 4.1 per cent in 2020 and a solid gain of 3.4 per cent is anticipated this year.

 

Quebec: The resurgence of COVID-19 toward the end of 2020 has had a significant effect on the province of Quebec. A deceleration in GDP growth in the final quarter of 2020 will give way to a contraction of 1.1 per cent in the first quarter of 2021. As several consumer-facing industries remain unable to make any significant progress, the potential for a full recovery of output continues to hinge on the speed at which the province can safely reopen. Taken together, we forecast the economy to grow by 4.5 per cent in 2021 and 3.9 per cent in 2022.

 

Ontario: Ontario’s economy has had more difficulties in dealing with COVID-19 compared with other regions of the country mainly because of a slower re-opening in the spring and the fact that Toronto has faced at least some restrictions for much of the year. Housing was one of the few sectors of the Ontario economy to expand during the pandemic due to rock bottom interest rates. The latest provincial budget indicated that the government plans to boost infrastructure spending through 2023. In all, we expect real GDP to expand by 4.5 per cent this year in the wake of a 5.5 per cent drop in 2020.

 

Manitoba: The province was successful at controlling the spread of COVID-19 last spring and summer, but this situation changed sharply last autumn as a surge in infections forced the provincial government to move into the “red zone.” We expect the economy shrank by 4.0 per cent in 2020 but will grow by 4.3 per cent in 2021.

 

 

Saskatchewan: The Saskatchewan economy declined 5.2 per cent in 2020 as the province suffered a steeper recession than many due to the combined effects of closures and low resource prices. But a recovery of 5.4 per cent is expected this year, with an additional 2.4 per cent gain forecast for 2022.

 

Alberta: The rollout of vaccines, which could see large swaths of the population vaccinated by mid-year, a positive outlook for oil and natural gas prices, and healthy household finances are behind our view that Alberta’s economy and labour market will strengthen over 2021. Alberta will experience the largest increase in real GDP in 2021 as the 8.0 per cent plunge in economy activity last year will set the stage for a rebound of 6.4 per cent this year.

 

British Columbia: Last year, B.C. recorded a drop in real GDP of 4.7 per cent, but better days are ahead as we expect the economy to rebound and expand by 4.9 per cent this year. Labour markets have managed to recover a larger share of the jobs lost during the height of the pandemic last April and May compared with the rest of the country. This trend continued in January of this year as the province recorded a slight increase in jobs compared with large declines in central Canada.

 

The full provincial outlook is available for subscribers here.

 

About the Conference Board of Canada:

The Conference Board of Canada is the country’s leading independent research organization. Our mission is to empower and inspire leaders to build a stronger future for all Canadians through our trusted research and unparalleled connections. Follow The Conference Board of Canada on Twitter @ConfBoardofCda

 

Media Contact:

The Conference Board of Canada

[email protected]  / 613-526-3090 ext. 224

Corp Comm
The Conference Board of Canada
6135263090 ext. 224
[email protected]

• Rocco Venezia Appointed Chief Accounting Officer and Acting CFO –
• Intercept Reiterates 2021 Financial Guidance –

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Sandip Kapadia, Chief Financial Officer, will leave Intercept to pursue another opportunity. Mr. Kapadia will continue to serve as Chief Financial Officer until his departure on March 26, 2021. The Company also announced Mr. Rocco Venezia will be appointed Chief Accounting Officer and will serve as acting Chief Financial Officer until a permanent replacement is announced.

“Sandip joined Intercept shortly after the approval of Ocaliva in the U.S. and played an important role supporting the growth of the Company from a clinical stage to a commercial organization,” said Jerry Durso, President and Chief Executive Officer of Intercept. “On behalf of the Intercept team, I want to thank Sandip for his contributions. Sandip has built a talented and experienced team at Intercept, and I’m very pleased to announce that Rocco Venezia will be appointed Chief Accounting Officer. Rocco has served as Intercept’s Controller since 2016 and brings over 20 years of relevant finance and accounting experience to the role.”

“I want to thank my colleagues at Intercept for their partnership over the years as we built the Ocaliva franchise and advanced the NASH program to bring important therapies to patients with non-viral liver diseases,” said Mr. Kapadia. “I’m confident the team, under Jerry’s leadership, will continue to achieve its objectives and deliver long-term value to investors, healthcare providers and patients.”

Mr. Kapadia’s departure is not related to Intercept’s operations, financial reporting or controls and the Company reiterates its full year 2021 financial guidance.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis (“NASH”), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or “OCA”) for primary biliary cholangitis (“PBC”), and our product candidates, including OCA for liver fibrosis due to NASH, the timing and acceptance of our regulatory filings and the potential approval of OCA for liver fibrosis due to NASH, the review of our New Drug Application for OCA for the treatment of liver fibrosis due to NASH by the U.S. Food and Drug Administration (“FDA”), our intent to work with the FDA to address the issues raised in a complete response letter (“CRL”), the potential commercial success of OCA, as well as our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans and objectives.

These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “possible,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates on an accelerated basis or at all, including OCA for liver fibrosis due to NASH following the issuance of the CRL by the FDA; any advisory committee recommendation or dispute resolution determination that our product candidates, including OCA for liver fibrosis due to NASH, should not be approved or approved only under certain conditions; any future determination that the regulatory applications and subsequent information we submit for our product candidates, including OCA for liver fibrosis due to NASH, do not contain adequate clinical or other data or meet applicable regulatory requirements for approval; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, including OCA for liver fibrosis due to NASH, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), any risk mitigation programs such as a REMS, and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for liver fibrosis due to NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions, or otherwise limit the sale of such product or product candidate, including in connection with the newly identified safety signal relating to Ocaliva identified by the FDA in May 2020; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, retaining patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; the outcomes of ongoing discussions with the FDA and European Medicines Agency regarding the feasibility of the COBALT and 401 trials; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to successfully launch OCA for liver fibrosis due to NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators’ election to pursue research, development and commercialization activities; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to attract and retain key personnel to manage our business effectively; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; the impact of COVID-19, including any impact on our results of operations or financial position, related quarantines and government actions, delays relating to our regulatory applications, disruptions relating to our ongoing clinical trials or involving our contract research organizations, study sites or other clinical partners, disruptions relating to our supply chain or involving our third-party manufacturers, distributors or other distribution partners, facility closures or other restrictions, and the extent and duration thereof; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the potential impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020.

CONTACT

For more information about Intercept, please contact: 

Investors
[email protected] 

Media
[email protected] 

Source: Intercept Pharmaceuticals, Inc.

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31^st Annual Oppenheimer Healthcare Conference on March 16, 2021 at 3:10 PM Eastern Time. The conference will be held virtually with participants joining remotely from March 16^th to the 18^th.

A webcast of the presentation can be followed live online via the link below: https://wsw.com/webcast/oppenheimer9/stsa/2746007 or please visit the “Events and Presentations” page within the “Investors” section of the Satsuma Pharmaceuticals website at www.satsumarx.com.

If you are interested in arranging a one-on-one meeting, please contact your Oppenheimer & Co. Inc. representative or contact Corey Davis at LifeSci Advisors.

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is in Phase 3 development and specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS

:         

Corey Davis, PhD
LifeSci Advisors, LLC
[email protected]

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
[email protected]